Search for: [Abstract = "r NF\-κB \(BAY 11– 7082\) inhibitors significantly reduced their expression. Analysis of mRNA \(RELA\) expression in VICs confirmed these results. In Publication 3, 50 patients with AS and lipoprotein\(a\) \[Lp\(a\)\] concentration ≥50 mg\/dl were evaluated, along with 20 patients with AS and Lp\(a\) <50 mg\/dl. Valvular OxPL expression was assessed using immunofluorescence. The levels of OxPL, plasminogen activator inhibitor type 1 \(PAI\-1\) antigen, and thrombin\-activated fibrinolysis inhibitor \(TAFI\) were evaluated using ELISA tests. Clot lysis time \(CLT\) in plasma was determined turbidimetrically. AS patients with Lp\(a\) ≥50 mg\/dl had increased OxPL valvular expression and higher serum levels of OxPL compared to patients with AS and Lp\(a\) <50 mg\/dl. Valvular OxPL expression correlated with serum OxPL and Lp\(a\) levels. Only in patients with Lp\(a\) ≥50 mg\/dl, serum OxPL levels correlated with CLT, PAI\-1 and TAFI concentrations, as well as the severity of AS. Multifactorial regression analysis showed that higher levels of OxPL were associated with prolonged CLT in patients with AS and Lp\(a\) ≥50 mg\/dl. In Publication 4, 75 patients with severe AS were examined. Valvular lipid accumulation was assessed histochemically, while the expression of PAI\-1 and NF\-κB was evaluated using immunofluorescence. Valves obtained from autopsy donors served as controls. The expression of PAI\-1 in V"]

Number of results: 1